BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
PRODID:-//Telerik Inc.//Sitefinity CMS 14.4//EN
BEGIN:VTIMEZONE
TZID:Mountain Standard Time
BEGIN:STANDARD
DTSTART:20251102T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYHOUR=2;BYMINUTE=0;BYMONTH=11
TZNAME:Mountain Standard Time
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250301T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYHOUR=2;BYMINUTE=0;BYMONTH=3
TZNAME:Mountain Daylight Time
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:RSVP Here\n\n\nDate : Feb 20\nPlace: Fulginiti Pavilion\nTime 5
 -7pm\nSpeaker: David C. Swinney\, PhD\nChief Executive Officer&nbsp\;\niRN
 D3\n\nLearn more about Dr. Swinney in this interview.\nDr. Swinney is co-f
 ounder of&nbsp\;iRND3&nbsp\;and has over 20 years broad experience with Sy
 ntex and Roche as a leader in pre-clinical drug discovery\, primarily in t
 he inflammation and virology disease areas. His previous position was Dire
 ctor of Virology Biochemical Pharmacology at Roche Palo Alto. Dr. Swinney 
 has devoted the majority of his career to the identification of tractable 
 drug targets\, effective mechanisms of drug action\, and promising leads a
 nd clinical candidates to address unmet medical needs. He has also develop
 ed an expertise in the understanding and application of binding kinetics o
 f drug discovery. Dr. Swinney has a PhD in medicinal chemistry from the Un
 iversity of Washington and is author of over 100 publications in the field
 s of biochemistry and pharmacology.\n\n\n\n\n\n    a.CUI:link\, a.CUI:visi
 ted {\n    background: #cfb87c\;\n    border: none\;\n    color: black\;\n
     min-width: 300px\;\n    padding: 15px 32px\;\n    max-width: 300px\;\n
     text-align: center\;\n    text-decoration: none\;\n    display: inline
 -block\;\n    font-size: 16px\;\n    font-weitght: 400\;\n    font-family:
  Helvetica\, Arial\, sans-serif\;\n    margin: 4px 2px\;\n    cursor: poin
 ter\;\n    border-radius: 4px\;\n    -webkit-transition-duration: 0.4s\; /
 * Safari */\n    transition-duration: 0.4s\;\n    }\n    a.CUI:hover\, a.C
 UI:active {\n    box-shadow: 0 12px 16px 0 rgba(0\,0\,0\,0.24)\,0 17px 50p
 x 0 rgba(0\,0\,0\,0.19)\;\n    }\n    a:hover {\n    cursor:pointer\;\n   
  }\n
DTEND:20190221T020000Z
DTSTAMP:20260312T103801Z
DTSTART:20190221T000000Z
LOCATION:
SEQUENCE:0
SUMMARY:SPARK 15: The role of molecular mechanism of action in drug discove
 ry strategies
UID:RFCALITEM639089086818404460
X-ALT-DESC;FMTTYPE=text/html:<a href="http://bit.ly/SPARK15F" target="_blan
 k" class="CUI">RSVP Here</a>\n<br />\n<br />\n<p>Date : Feb 20<br />\nPlac
 e: Fulginiti Pavilion<br />\nTime 5-7pm</p>\n<p>Speaker: <strong>David C. 
 Swinney\, PhD</strong><br />\n<em>Chief Executive Officer</em>&nbsp\;<br /
 >\niRND3<br />\n<br />\nLearn more about Dr. Swinney in this <a href="http
 s://www.collaborativedrug.com/spotlight-interview-with-dr-david-swinney-ce
 o-of-the-institute-for-rare-and-neglected-diseases-drug-discovery/" target
 ="_blank">interview</a>.</p>\n<p>Dr. Swinney is co-founder of&nbsp\;iRND3&
 nbsp\;and has over 20 years broad experience with Syntex and Roche as a le
 ader in pre-clinical drug discovery\, primarily in the inflammation and vi
 rology disease areas. His previous position was Director of Virology Bioch
 emical Pharmacology at Roche Palo Alto. Dr. Swinney has devoted the majori
 ty of his career to the identification of tractable drug targets\, effecti
 ve mechanisms of drug action\, and promising leads and clinical candidates
  to address unmet medical needs. He has also developed an expertise in the
  understanding and application of binding kinetics of drug discovery. Dr. 
 Swinney has a PhD in medicinal chemistry from the University of Washington
  and is author of over 100 publications in the fields of biochemistry and 
 pharmacology.<br />\n<br />\n<br />\n</p>\n<img alt="" src="https://www.th
 oughtco.com/thmb/s1ULeFRcnUdd0EPpmiC7OvS8hCw=/768x0/filters:no_upscale():m
 ax_bytes(150000):strip_icc()/GettyImages-1577425351-58f0b7d45f9b582c4d5f50
 c0.jpg" /><img alt="" />\n<style>\n    a.CUI:link\, a.CUI:visited {\n    b
 ackground: #cfb87c\;\n    border: none\;\n    color: black\;\n    min-widt
 h: 300px\;\n    padding: 15px 32px\;\n    max-width: 300px\;\n    text-ali
 gn: center\;\n    text-decoration: none\;\n    display: inline-block\;\n  
   font-size: 16px\;\n    font-weitght: 400\;\n    font-family: Helvetica\,
  Arial\, sans-serif\;\n    margin: 4px 2px\;\n    cursor: pointer\;\n    b
 order-radius: 4px\;\n    -webkit-transition-duration: 0.4s\; /* Safari */\
 n    transition-duration: 0.4s\;\n    }\n    a.CUI:hover\, a.CUI:active {\
 n    box-shadow: 0 12px 16px 0 rgba(0\,0\,0\,0.24)\,0 17px 50px 0 rgba(0\,
 0\,0\,0.19)\;\n    }\n    a:hover {\n    cursor:pointer\;\n    }\n</style>
END:VEVENT
END:VCALENDAR